Takeda Pharmaceutical (TAK) Receivables: 2018-2025

Historic Receivables for Takeda Pharmaceutical (TAK) over the last 8 years, with Mar 2025 value amounting to $5.4 billion.

  • Takeda Pharmaceutical's Receivables rose 3.95% to $5.4 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $11.8 billion, marking a year-over-year decrease of 18.82%. This contributed to the annual value of $5.4 billion for FY2025, which is 1.31% up from last year.
  • As of FY2025, Takeda Pharmaceutical's Receivables stood at $5.4 billion, which was up 1.31% from $5.4 billion recorded in FY2024.
  • Takeda Pharmaceutical's 5-year Receivables high stood at $8.1 billion for FY2021, and its period low was $493.3 million during FY2023.
  • Moreover, its 3-year median value for Receivables was $5.4 billion (2024), whereas its average is $3.8 billion.
  • Its Receivables has fluctuated over the past 5 years, first tumbled by 92.38% in 2022, then skyrocketed by 988.86% in 2024.
  • Yearly analysis of 5 years shows Takeda Pharmaceutical's Receivables stood at $8.1 billion in 2021, then plummeted by 92.38% to $621.1 million in 2022, then dropped by 20.58% to $493.3 million in 2023, then surged by 988.86% to $5.4 billion in 2024, then climbed by 1.31% to $5.4 billion in 2025.